Full Press Release Details
TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION NOVEMBER 2020Exhibit 99.1 FORTE BIOSCIENCES TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION NOVEMBER 2020
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain
statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation
Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking
statement can be guaranteed, and actual results may differ materially from those projected. Forte Biosciences, Inc. ("we", the "Company" or "Forte") undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects,"
"projects," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue,"
"guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve
risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to the sufficiency of the Company's cash
balance to fund the Company's activities, and the expectation with respect thereto; the business and prospects of the Company; Forte's plans to develop and potentially commercialize its product candidates, including FB-401; the timing of
initiation of Forte's planned clinical trials; the timing of the availability of data from Forte's clinical trials; the timing of any planned investigational new drug application or new drug application; Forte's plans to research,
develop and commercialize its current and future product candidates; Forte's ability to successfully enter into collaborations, and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits
and market acceptance of Forte's product candidates; Forte's commercialization, marketing and manufacturing capabilities and strategy; Forte's ability to identify additional products or product candidates with significant
commercial potential; developments and projections relating to Forte's competitors and its industry; the impact of government laws and regulations; Forte's ability to protect its intellectual property position; Forte's estimates
regarding future revenue, expenses, capital requirements and need for additional financing following the proposed transaction; and the impact of COVID-19 on the Company, the Company's industry or the economy generally. The known risks
and uncertainties are described in detail under the caption "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K for the year ending December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended
September 30, 2020, and the Registration Statement/Proxy Statement/Prospectus filed on Form S-4 (Registration No. 333- 237371), initially filed on March 25, 2020, as amended, and declared effective by the Securities and Exchange Commission, or SEC,
on May 13, 2020, and our subsequent reports filed with the SEC and other documents filed from time to time with the SEC. Forward-looking statements included in this presentation are based on information available to Forte as of the date of this
presentation. Accordingly, our actual results may materially differ from our current expectations, estimates and projections. Forte undertakes no obligation to update such forward-looking statements to reflect events or circumstances after the date
of this presentation. 2CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of
the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future,
and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Forte Biosciences, Inc. ("we", the
"Company" or "Forte") undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as
"anticipates," "believes," "plans," "expects," "projects," "intends," "may," "will," "should," "could," "estimates,"
"predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.
Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not
limited to, risks relating to the sufficiency of the Company's cash balance to fund the Company's activities, and the expectation with respect thereto; the business and prospects of the Company; Forte's plans to develop and
potentially commercialize its product candidates, including FB-401; the timing of initiation of Forte's planned clinical trials; the timing of the availability of data from Forte's clinical trials; the timing of any planned
investigational new drug application or new drug application; Forte's plans to research, develop and commercialize its current and future product candidates; Forte's ability to successfully enter into collaborations, and to fulfill its
obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of Forte's product candidates; Forte's commercialization, marketing and manufacturing capabilities and strategy;
Forte's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Forte's competitors and its industry; the impact of government laws and regulations;
Forte's ability to protect its intellectual property position; Forte's estimates regarding future revenue, expenses, capital requirements and need for additional financing following the proposed transaction; and the impact of COVID-19 on
the Company, the Company's industry or the economy generally. The known risks and uncertainties are described in detail under the caption "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K for the
year ending December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and the Registration Statement/Proxy Statement/Prospectus filed on Form S-4 (Registration No. 333- 237371), initially filed on March 25, 2020, as
amended, and declared effective by the Securities and Exchange Commission, or SEC, on May 13, 2020, and our subsequent reports filed with the SEC and other documents filed from time to time with the SEC. Forward-looking statements included in this
presentation are based on information available to Forte as of the date of this presentation. Accordingly, our actual results may materially differ from our current expectations, estimates and projections. Forte undertakes no obligation to update
such forward-looking statements to reflect events or circumstances after the date of this presentation. 2
SUMMARY OF FORTE BIOSCIENCES: FB-401 - POTENTIAL FIRST-IN-CLASS
TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well LATE-STAGE tolerated and demonstrated clinical improvement
Randomized Phase 2 initiation in adults and pediatrics CLINICAL ASSET 2 years and older commenced in 3Q20 in atopic dermatitis (AD) with data readout expected in mid-2021 LARGE MARKET 10-20% of children in industrialized countries develop
atopic dermatitis (AD) WITH UNMET In the U.S., AD affects 17 million people (over 50% are children) NEED Significant unmet need for safe and effective AD therapy for pediatrics POTENTIAL FIRST- Clinical data demonstrates FB-401
was well-tolerated and active IN-CLASS TOPICAL Phase 2a study, including pediatrics, demonstrates potential for acceptable safety profile and significant LIVE reduction in atopic dermatitis disease and pruritus, as well as control of S.
aureus while BIOTHERAPEUTIC tapering/eliminating steroid use Exclusive license to NIH-owned patent families as well as Forte owned IP. Coverage includes INTELLECTUAL composition and method of use patents PROPERTY Patent coverage
through at least 2037 (7 U.S. patents issued) Experienced life science investor base including Alger, ArrowMark, BVF Partners LP, Franklin Templeton FINANCING / and OrbiMed MANAGEMENT Additional high-quality investors brought in with
$46 m secondary offering in October 2020 Management team with significant drug development, innovation and corporate strategy experience 3SUMMARY OF FORTE BIOSCIENCES: FB-401 - POTENTIAL FIRST-IN-CLASS TOPICAL LIVE BIOTHERAPEUTIC FOR
THE TREATMENT OF INFLAMMATORY SKIN DISEASE Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well LATE-STAGE tolerated and demonstrated clinical improvement Randomized Phase 2 initiation in
adults and pediatrics CLINICAL ASSET 2 years and older commenced in 3Q20 in atopic dermatitis (AD) with data readout expected in mid-2021 LARGE MARKET 10-20% of children in industrialized countries develop atopic dermatitis (AD) WITH UNMET
In the U.S., AD affects 17 million people (over 50% are children) NEED Significant unmet need for safe and effective AD therapy for pediatrics POTENTIAL FIRST- Clinical data demonstrates FB-401 was well-tolerated and active
IN-CLASS TOPICAL Phase 2a study, including pediatrics, demonstrates potential for acceptable safety profile and significant LIVE reduction in atopic dermatitis disease and pruritus, as well as control of S. aureus while BIOTHERAPEUTIC
tapering/eliminating steroid use Exclusive license to NIH-owned patent families as well as Forte owned IP. Coverage includes INTELLECTUAL composition and method of use patents PROPERTY Patent coverage through at least 2037 (7 U.S.
patents issued) Experienced life science investor base including Alger, ArrowMark, BVF Partners LP, Franklin Templeton FINANCING / and OrbiMed MANAGEMENT Additional high-quality investors brought in with $46 m secondary offering in
October 2020 Management team with significant drug development, innovation and corporate strategy experience 3
FORTE BIOSCIENCES: OVERVIEW OF FB-401 FB-401 drug product
consists of 3 therapeutic bacterial strains of commensal gram negative R. mucosa specifically selected based on screening for impact on inflammatory skin disease parameters Topical application of the specifically selected therapeutic
bacterial strains of R. mucosa drug product: Drives immune pathways that are defective Suppresses Staphylococcus aureus growth Improves skin barrier function Clinical data demonstrates FB-401 live biotherapeutic therapy
was well-tolerated and active in both adults and pediatric Phase 2a study, including pediatrics, well tolerated and demonstrated clinical improvement in atopic dermatitis disease and pruritus, as well as control of S. aureus while
tapering/eliminating steroid use Randomized Phase 2 trial initiation commenced in 3Q20 FDA granted Fast Track designation to FB-401 for the treatment of atopic dermatitis 4FORTE BIOSCIENCES: OVERVIEW OF FB-401 FB-401 drug
product consists of 3 therapeutic bacterial strains of commensal gram negative R. mucosa specifically selected based on screening for impact on inflammatory skin disease parameters Topical application of the specifically selected therapeutic
bacterial strains of R. mucosa drug product: Drives immune pathways that are defective Suppresses Staphylococcus aureus growth Improves skin barrier function Clinical data demonstrates FB-401 live biotherapeutic therapy
was well-tolerated and active in both adults and pediatric Phase 2a study, including pediatrics, well tolerated and demonstrated clinical improvement in atopic dermatitis disease and pruritus, as well as control of S. aureus while
tapering/eliminating steroid use Randomized Phase 2 trial initiation commenced in 3Q20 FDA granted Fast Track designation to FB-401 for the treatment of atopic dermatitis 4
EXPERIENCED MANAGEMENT AND ADVISORY TEAMS Forte BioSciences team
has extensive experience in microbial manufacturing, quality, regulatory and clinical development in dermatology Paul Wagner, Ph.D. - CEO Dan Burge, MD - Head of Clinical Development Eric Emery - Head of Downstream Manufacturing
Tony Riley - Chief Financial Officer Hank Talbot, Ph.D. - Head of Process Development and Quality Scientific Advisory Board (SAB) Prof. Amy Paller, MD - Chair, Department of Dermatology Northwestern University Feinberg
School of Medicine Prof. Lawrence Eichenfield, MD - Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego, Editor in Chief of Pediatric Dermatology Prof. Eric Simpson, MD -Professor of
Dermatology, Oregon Health & Science University, Portland Dr. Patricia Walker, MD, Ph.D. - Former CMO of Allergan Medical and Dermatology TA Head 5EXPERIENCED MANAGEMENT AND ADVISORY TEAMS Forte BioSciences team has extensive
experience in microbial manufacturing, quality, regulatory and clinical development in dermatology Paul Wagner, Ph.D. - CEO Dan Burge, MD - Head of Clinical Development Eric Emery - Head of Downstream Manufacturing Tony Riley
- Chief Financial Officer Hank Talbot, Ph.D. - Head of Process Development and Quality Scientific Advisory Board (SAB) Prof. Amy Paller, MD - Chair, Department of Dermatology Northwestern University Feinberg School of
Medicine Prof. Lawrence Eichenfield, MD - Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego, Editor in Chief of Pediatric Dermatology Prof. Eric Simpson, MD -Professor of Dermatology,
Oregon Health & Science University, Portland Dr. Patricia Walker, MD, Ph.D. - Former CMO of Allergan Medical and Dermatology TA Head 5
ATOPIC DERMATITIS Atopic dermatitis (AD) is characterized by
itching, a scaly rash, dry skin, and cutaneous sensitization to allergens. The underlying pathology of AD consists of a triad of defective skin barrier function, susceptibility to Staphylococcus aureus skin infection, and immune imbalance
(overactive adaptive immunity in lieu of innate immunity) 10-20% of children in industrialized countries develop atopic dermatitis with increasing incidence. 80% of children with severe disease continue to have lifelong exacerbations
There is currently no cure for AD In the US, the prevalence of atopic dermatitis is approximately 17 million More than half of that prevalence is pediatric (<17 years old) Treatment options for pediatrics are very limited
Lichenified, Erythematous ill- erythematous plaques defined patches Affects flexural behind the knees with overlying areas of neck, scale and erosions Erythematous, elbows, knees, on her cheeks excoriated papules with wrists, and overlying crust in
the ankles antecubital fossa FDA Pediatric Subcommittee October 29-30, 2003 American Academy of Dermatology 6ATOPIC DERMATITIS Atopic dermatitis (AD) is characterized by itching, a scaly rash, dry skin, and cutaneous sensitization to
allergens. The underlying pathology of AD consists of a triad of defective skin barrier function, susceptibility to Staphylococcus aureus skin infection, and immune imbalance (overactive adaptive immunity in lieu of innate immunity) 10-20% of
children in industrialized countries develop atopic dermatitis with increasing incidence. 80% of children with severe disease continue to have lifelong exacerbations There is currently no cure for AD In the US, the prevalence of atopic
dermatitis is approximately 17 million More than half of that prevalence is pediatric (<17 years old) Treatment options for pediatrics are very limited Lichenified, Erythematous ill- erythematous plaques defined patches Affects
flexural behind the knees with overlying areas of neck, scale and erosions Erythematous, elbows, knees, on her cheeks excoriated papules with wrists, and overlying crust in the ankles antecubital fossa FDA Pediatric Subcommittee October 29-30, 2003
American Academy of Dermatology 6
SKIN MICROBIOME The skin is a complex barrier organ characterized by
symbiotic relationship between microbial communities and host tissue via complex signals provided by the innate and the adaptive immune systems Exposure to various endogenous and exogenous factors impact the system balance potentially leading to
inflammatory skin conditions comprising infections, allergies or autoimmune diseases Researchers in microbiology and dermatology identified and characterized the microorganisms present on the skin, to evaluate the bacterial diversity and their
relative abundance and to understand how microbial diversity may contribute to skin health and dermatological conditions Recent work has revealed that the skin microbiome is significantly different between healthy controls and patients with AD and
that symptoms are associated with a loss of commensal diversity Dreno et al, European Academy of Dermatology and Venerology 2016, 30, 2038-2047 7 Kong HH et al. Genome research. 2012;22(5):850-859SKIN MICROBIOME The skin is a complex barrier organ
characterized by symbiotic relationship between microbial communities and host tissue via complex signals provided by the innate and the adaptive immune systems Exposure to various endogenous and exogenous factors impact the system balance
potentially leading to inflammatory skin conditions comprising infections, allergies or autoimmune diseases Researchers in microbiology and dermatology identified and characterized the microorganisms present on the skin, to evaluate the bacterial
diversity and their relative abundance and to understand how microbial diversity may contribute to skin health and dermatological conditions Recent work has revealed that the skin microbiome is significantly different between healthy controls and
patients with AD and that symptoms are associated with a loss of commensal diversity Dreno et al, European Academy of Dermatology and Venerology 2016, 30, 2038-2047 7 Kong HH et al. Genome research. 2012;22(5):850-859
SKIN MICROBIOME DIFFERENCES IN ATOPIC DERMATITIS Genetic-based
microbiome identification revealed significant differences in the Gram-negative skin biome between atopic dermatitis (AD) patients and healthy controls (HV) NIH (Myles et. al.) identified substantial differences in the gram-negative microbiome
present on the skin of AD patients and healthy volunteers The predominant species of skin commensal Gram-negative bacteria (CGN) in HV found to be Roseomonas mucosa Over 50% of AD patients did not have any culturable Gram- negative flora, consistent
with DNA-based analysis Myles IA, Williams KW, Reckhow JD, et al. JCI Insight. 2016;1(10) Kong HH et al. Genome research. 2012;22(5):850-859 8SKIN MICROBIOME DIFFERENCES IN ATOPIC DERMATITIS Genetic-based microbiome identification revealed
significant differences in the Gram-negative skin biome between atopic dermatitis (AD) patients and healthy controls (HV) NIH (Myles et. al.) identified substantial differences in the gram-negative microbiome present on the skin of AD patients and
healthy volunteers The predominant species of skin commensal Gram-negative bacteria (CGN) in HV found to be Roseomonas mucosa Over 50% of AD patients did not have any culturable Gram- negative flora, consistent with DNA-based analysis Myles IA,
Williams KW, Reckhow JD, et al. JCI Insight. 2016;1(10) Kong HH et al. Genome research. 2012;22(5):850-859 8
MECHANISM OF FB-401 Extensive preclinical work by Forte in collaboration
with NIH, investigating the activity of FB-401 has demonstrated: 1) FB-401 activates tissue repair and anti-inflammation pathways in keratinocytes, dendritic cells and fibroblasts 1) Gene sequencing of the FB-401 strains and mRNAseq highlights the
activation of TLR5, TNFR and CXCR2 (IL-8 signaling) 2) FB-401 inhibits S. aureus through metabolites produced by the 3 strains of R. mucosa 1) The 3 strains of R mucosa were specifically selected based on their ability to suppress different strains